Jefferies & Co. is out with a research report on Luminex Corp LMNX and is raising its price target to $18 from $17, and it has a Hold rating on shares.
In a note to clients, Jefferies & Co. writes, "LMNX's 2Q11 non-GAAP EPS of $0.14 was $0.08 ahead of consensus on vastly stronger revenue growth and profit trends. We are raising our 2011 and 2012 EPS forecast to $0.40 (from $0.30) and $0.55 (from $0.45) respectively. Our price target moves to $18 (from $17) on higher cash flow forecasts."
Shares of LMNX lost $1.18 yesterday to close at $18.50, a loss of 6%.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsHealth CareJefferies & Co.Life Sciences Tools & Services
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in